Cargando…

MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES

BACKGROUND: Wnt+ medulloblastoma (WPM) is a favorable subtype with EFS > 90% when treating postoperatively with craniospinal irradiation and posterior fossa boost (CSI/XRT) followed by adjuvant chemotherapy. This pilot study explored the safety of omitting radiation in standard-risk WPM. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Kenneth, Chi, Susan, Hawkins, Cynthia, Rodriguez, Fausto, London, Wendy, Castellino, Robert Craig, Aguilera, Dolly, Stapleton, Stacie, Ashley, David, Landi, Daniel, Bandopadhayay, Pratiti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Medulloblastoma (Clinical)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715534/ http://dx.doi.org/10.1093/neuonc/noaa222.501

Ejemplares similares

MBCL-52. ENDOCRINE PROFILE AFTER MEDULLOBLASTOMA TREATMENT
por: Pavon-Mengual, Miriam, et al.
Publicado: (2020)

MBCL-27. ASSOCIATION OF MEDULLOBLASTOMA WITH CHARCOT-MARIE-TOOTH DISEASE
por: Watanabe, Kenichiro, et al.
Publicado: (2020)

MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
por: Robinson, Giles W, et al.
Publicado: (2020)

MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL
por: Dietzsch, Stefan, et al.
Publicado: (2020)

MEDB-45. Functional genomics identifies epigenetic regulators as novel therapeutic targets for sonic hedgehog medulloblastoma
por: Tsiami, Foteini, et al.
Publicado: (2022)

MBCL-35. SALVAGE RADIATION THERAPY FOR PROGRESSIVE AND/OR RELAPSED PEDIATRIC MEDULLOBLASTOMA
por: Baig, Muhammad, et al.
Publicado: (2020)

MBCL-48. OUTCOMES OF TREATMENT BASED ON THE ST. JUDE MEDULLOBLASTOMA-96 REGIMEN FOR JAPANESE CHILDREN WITH MEDULLOBLASTOMA
por: Fujimura, Junya, et al.
Publicado: (2020)

MBCL-41. LYMPHOHEMATOPOIETIC TOXICITY IDENTIFIED IN PATIENTS WITH MEDULLOBLASTOMA RECEIVING CRANIOSPINAL IRRADIATION
por: Watanabe, Atsuko, et al.
Publicado: (2020)

MBCL-08. INTEGRATIVE MOLECULAR ANALYSIS OF PATIENT-MATCHED DIAGNOSTIC AND RELAPSED MEDULLOBLASTOMAS
por: Kumar, Rahul, et al.
Publicado: (2020)

MEDB-73. Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma
por: Lupien, Leslie, et al.
Publicado: (2022)

MBCL-30. NOVEL SMO MUTATION IN DESMOPLASTIC/NODULAR MEDULLOBLASTOMA: A CASE REPORT
por: Wright, Avery, et al.
Publicado: (2020)

MBCL-31. TREATMENT RESULTS AMONG 106 PATIENTS WITH MEDULLOBLASTOMA OF MOLECULAR SUBGROUP 3
por: Zheludkova, Olga, et al.
Publicado: (2020)

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH
por: Slavc, Irene, et al.
Publicado: (2020)

MBCL-02. ROLE OF PREOPERATIVE CHEMOTHERAPY IN METASTATIC MEDULLOBLASTOMA: A COMPARATIVE STUDY IN 92 CHILDREN
por: Guerrini-Rousseau, Léa, et al.
Publicado: (2020)

MBCL-32. HIGH-DOSE CHEMOTHERAPY WITH STEM CELL RESCUE FOR RECURRENT PREVIOUSLY IRRADIATED MEDULLOBLASTOMA
por: Salnikova, Ekaterina, et al.
Publicado: (2020)

MBCL-50. DISMAL OUTCOME OF HIGH RISK MEDULLOBLASTOMA TREATED WITH CHEMOTHERAPY FIRST APPROACH IN MALAYSIA
por: Quah, Shiao Wei, et al.
Publicado: (2020)

MBCL-33. RARE PULMONARY TOXICITY IN THREE MEDULLOBLASTOMA PATIENTS UNDERGOING ANTIANGIOGENIC METRONOMIC COMBINATION THERAPY
por: Lenzen, Alicia, et al.
Publicado: (2020)

MBCL-12. MOLECULAR SIGNATURES AND TUMOR INFILTRATING IMMUNOLOGICAL CELLS ASSOCIATED WITH ASIAN MEDULLOBLASTOMA PATIENT SURVIVAL
por: Liang, Kung-Hao, et al.
Publicado: (2020)

MBCL-10. LOCAL RECURRENCE AND SURVIVAL OUTCOMES OF MEDULLOBLASTOMA (MB) IN ADOLESCENT AND YOUNG ADULT PATIENTS (AYA)
por: Rongthong, Warissara, et al.
Publicado: (2020)

MBCL-24. CAN YOUNG CHILDREN WITH RELAPSED MEDULLOBLASTOMA BE SALVAGED AFTER INITIAL IRRADIATION-SPARING APPROACHES?
por: Erker, Craig, et al.
Publicado: (2020)

MBCL-18. ANALYSIS OF DNA METHYLATION PROFILES OF PEDIATRIC MEDULLOBLASTOMAS: EXPERIENCE AT THE BAMBINO GESÙ CHILDREN’S HOSPITAL
por: Miele, Evelina, et al.
Publicado: (2020)

MEDB-02. The identification and functional characterization of circular RNA Circ_63706 in sonic hedgehog medulloblastomas
por: Pokhrel, Rudramani, et al.
Publicado: (2022)

MBCL-17. METASTATIC MEDULLOBLASTOMA CAN BE CURED WITHOUT EXCISION OF THE PRIMARY TUMOR: A SINGLE CENTER EXPERIENCE
por: Dvir, Rina, et al.
Publicado: (2020)

MBCL-14. A STUDY OF LOW-DOSE CRANIOSPINAL RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA
por: Mochizuki, Aaron, et al.
Publicado: (2020)

MBCL-04. 5 – AZACYTIDINE IN TREATMENT OF CHILDREN WITH DE NOVO AND RELAPSED METASTATIC MEDULLOBLASTOMA: RESULTS OF INTERCENTER PILOT STUDY
por: Levashov, Andrey, et al.
Publicado: (2020)

MBCL-22. EFFICACY OF DOUBLE-CONDITIONING REGIMEN COMPRISING THIOTEPA AND MELPHALAN FOR RELAPSED MEDULLOBLASTOMA – A SINGLE INSTITUTION EXPERIENCE
por: Yamasaki, Kai, et al.
Publicado: (2020)

MBCL-03. RESULTS OF HIGH-DOSE THIOTEPA, CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA
por: Gevorgian, Asmik, et al.
Publicado: (2020)

MEDB-03. Medulloblastoma cerebrospinal fluid reveals hypoxic indicators (metabolites and lipids) and cancer-specific RNAs
por: Lee, Bongyong, et al.
Publicado: (2022)

MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
por: Chintagumpala, Murali, et al.
Publicado: (2020)

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT
por: Mynarek, Martin, et al.
Publicado: (2020)

MBCL-05. TREATMENT OF CHILDREN WITH MEDULLOBLASTOMA WITHOUT METASTATIC INVOLVEMENT IN THE AGE GROUP OLDER THAN 3 YEARS: RESULTS OF INTERCENTER TRIAL
por: Levashov, Andrey, et al.
Publicado: (2020)

MEDB-32. Reducing treatment-related toxicity for children with WNT-activated medulloblastoma
por: Taylor, Jessica, et al.
Publicado: (2022)

MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?
por: Obrecht, Denise, et al.
Publicado: (2020)

MBCL-01. METHYLATION PROFILING OF PEDIATRIC MEDULLOBLASTOMA IN SAUDI ARABIA IN A CLINICAL SETTING PERMITS SUB-CLASSIFICATION AND REVEALS NEW OUTCOME PREDICTIONS
por: Alharbi, Musa, et al.
Publicado: (2020)

MBCL-46. TREATMENT OF RECURRENT WINGLESS-ACTIVATED MEDULLOBLASTOMA (Wnt-MB) INCORPORATING MARROW-ABLATIVE THIOTEPA AND CARBOPLATIN CHEMOTHERAPY (HDCx) AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE (AuHPCR): A DUAL REPORT
por: Harris, Micah K, et al.
Publicado: (2020)

MEDB-35. Relationship between genetic profile, histology, clinical features and long-term outcome in young children medulloblastoma (YCMB) treated with upfront high dose chemotherapy (HDCT) in Italy
por: Garrè, Maria Luisa, et al.
Publicado: (2022)

MBCL-28. LONG-TERM FOLLOW-UP RESULTS OF REDUCED DOSE CRANIOSPINAL RADIOTHERAPY AND TANDEM HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK MEDULLOBLASTOMA
por: Lee, Ji Won, et al.
Publicado: (2020)

MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

MEDB-27. Clinico-Radiological Outcomes in WNT-pathway Medulloblastoma: Retrospective Single Institutional Audit
por: Mani, Shakthivel, et al.
Publicado: (2022)

MEDB-01. Management of the risk of medulloblastoma associated to familial adenomatous polyposis and dysregulated Wnt signalosome
por: Abdelmoula, Balkiss, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_onm3111cino4r4sit1fkbmjn96